CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity is a research paper published in Blood (2021). On theSindex it has a DataRank of 0. It has been cited 222 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NCI NIH HHS
Grant: P01 CA094237
NCI NIH HHS
Grant: P50 CA126752
FWCI
11.35
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 2 of The development of chimeric antigen receptor T-cells against CD70 for renal cell carcinoma treatment
Additional file 2 of The development of chimeric antigen receptor T-cells against CD70 for renal cell carcinoma treatment
Additional file 1 of The development of chimeric antigen receptor T-cells against CD70 for renal cell carcinoma treatment
Additional file 1 of The development of chimeric antigen receptor T-cells against CD70 for renal cell carcinoma treatment
Additional file 1 of IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts
Additional file 1 of IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts